Influence of pravastatin, a specific inhibitor of hmg-coa reductase, on hepatic metabolism of cholesterol

New England Journal of Medicine

Volumn 323, Issue 4, 1990, Pages 224-228

  Reihnér, Eva ^a   Rudling, Mats ^a   Ståhlberg, Dagny ^a   Berglund, Lars ^a   Ewerth, Staffan ^a   Björkhem, Ingemar ^a   Einarsson, Kurt ^a   Angelin, bo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PRAVASTATIN;

ARTICLE; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER METABOLISM; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; PRIORITY JOURNAL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLELITHIASIS; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; NAPHTHALENES; PRAVASTATIN; RECEPTORS, LDL; STEROL O-ACYLTRANSFERASE;

EID: 0025345124     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199007263230403     Document Type: Article

References (41)

1. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: the Framingham Study. Arch Intern Med 1981; 141: 1128–31.
2. Steinberg D. Metabolism of lipoproteins and their role in the pathogenesis of atherosclerosis. Atheroscler Rev 1988; 18: 1–23.
3. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984; 25: 1570–6.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64.
5. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45.
6. Blankenhom DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233–40.
7. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl Med 1988; 319: 24–33.
8. Tobert JA, Bell GD, Birtwell J, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methyiglutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest 1982; 69: 913–9.
9. Mabuchi H, Haba T, Tatami R, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981; 305: 478–82.
10. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983; 80: 4124–8.
11. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multi-center study. Ann Intern Med 1987; 107: 609–15.
12. Nakaya N, Homma Y, Tamachi H, Shigematsu H, Hata Y, Goto Y. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemia subjects. JAMA 1987; 257: 3088–93.
13. Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A 1981; 78: 1194–8.
14. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptors in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 1986; 83: 8370–4.
15. Tsujita Y, Kuroda M, Shimada Y, el al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986; 877: 50–60.
16. Angelin B, Einarsson K, Liljeqvist L, Nilsell K, Heller RA. 3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme. J Lipid Res 1984; 25: 1159–66.
17. Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 26: Suppl 5: 32–7.
18. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882–4.
19. Lund E, Sisfontes L, Reihnér E. Björkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 1989; 49: 165–71.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75.
21. Björkhem I, Blomstrand R, Svensson L. Serum cholesterol determination by mass fragmentography. Clin Chim Acta 1974; 54: 185–93.
22. Schaffer R, Sniegoski LT, Welch MJ, et al. Comparison of two isotope dilution mass spectrometric methods for determination of total serum cholesterol. Clin Chem 1982; 28: 5–8.
23. Einarsson K, Angelin B, Ewerth S, Nilsell K, Björkhem I. Bile acid synthesis in man: assay of hepatic microsomal cholesterol 7 α-hydroxylase activity by isotope dilution-mass spectrometry. J Lipid Res 1986; 27: 82–8.
24. Einarsson K, Benthin L, Ewerth S, Hellers G. Ståhlberg D, Angelin B. Studies on acyl-coenzyme A: cholesterol acyltransferase activity in human liver microsomes. J Lipid Res 1989; 30: 739–46.
25. Rudling MJ, Peterson CO. A simple binding assay for the determination of low-density lipoprotein receptors in cell homogenates. Biochim Biophys Acta 1985; 833: 359–65.
26. Rudling MJ, Reihnér E, Einarsson K, Ewerth S, Angelin B. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Natl Acad Sci U S A 1990; 87: 3469–73.
27. Roda A, Festi D, Sama C, et al. Enzymatic determination of cholesterol in bile. Clin Chim Acta 1975; 64: 337–41.
28. Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer Chromatographic separation of polar lipids and determination of phospholipids by phosphorous analysis of spots. Lipids 1970; 5: 494–6.
29. Fausa O, Skålhegg BA. Quantitative determination of bile acids and their conjugates using thin-layer chromatography and a purified 3α-hydroxysteroid dehydrogenase. Scand J Gastroenterol 1974; 9: 249–54.
30. Carey MC. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 1979; 19: 945–55.
31. Angelin B, Einarsson K, Leijd B. Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 1979; 9: 185–90.
32. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1974.
33. Kempen JHM, Glatz JFC, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149–55.
34. Brown MS, Goldstein JL. The LDL receptor concept: clinical and therapeutic implications. Atheroscler Rev 1988; 18: 85–93.
35. Brown MS, Faust JR, Goldstein JL. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 1978; 253: 1121–8.
36. Sinensky M, Logel J. Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin. J Biol Chem 1983; 258: 8547–9.
37. Edwards PA, Lan S-F, Fogelman AM. Alterations in the rates of synthesis and degradation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase produced by cholestyramine and mevinolin. J Biol Chem 1983; 258: 10219–22.
38. Malmendier CL, Lontie J-F, Delcroix C, Magot T. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 1989; 80: 101–9.
39. Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci U S A 1984; 81: 2538–42.
40. Bilharz LE, Spady DK, Dietschy JM. Inappropriate hepatic cholesterol synthesis expands the cellular pool of sterol available for recruitment by bile acids in the rat. J Clin Invest 1989; 84: 1181–7.
41. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8: 1147–50.